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ABSTRACT
Purpose: We performed a phase I study to determine the maximum tolerable dose 
(MTD) and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain 
radiotherapy (WBRT) in patients with brain metastases (BM) from melanoma.
Methods: Based on intracranial (IC) disease burden, patients were treated with WBRT 
(Arm A) or SRS (Arm B). Ipilimumab starting dose was 3 mg/kg (every 3 weeks, starting 
on day 3 of WBRT or 2 days after SRS). Ipilimumab was escalated to 10 mg/kg using a 
two-stage, 3+3 design. The primary endpoint was to determine the MTD of ipilimumab 
combined with radiotherapy. Secondary endpoints were overall survival (OS), IC and 
extracranial (EC) control, progression free survival (PFS), and toxicity. This trial is regis-
tered with ClinicalTrials.gov, number NCT01703507.
Results: Characteristics of the 16 patients enrolled between 2011 and 2014 were: mean 
age, 60; median BM, 2 (1 to >10); number with EC disease, 13 (81%). Treatment included 
WBRT (n=5), SRS (n=11), ipilimumab 3mg/kg (n=7), 10 mg/kg (n=9). Median follow-up 
was 8 months (Arm A) and 10.5 months (Arm B). There were 21 grade 1-2 neuro-
toxic effects with no dose-limiting toxicities (DLTs). One patient experienced grade 3 
neurotoxicity prior to ipilimumab administration. Ten additional grade 3 toxicities were 
reported with gastrointestinal (n=5, 31%) 
as the most common. There were no 
grade 4/5 toxicities. Median PFS and OS, 
respectively, in Arm A were 2.5 months 
and 8 months, and in Arm B were 2.1 
months and not reached.
Conclusion: Concurrent ipilimumab 10 
mg/kg with SRS is safe. The WBRT arm 
was closed early due to slow accrual, but 
demonstrated safety with ipilimumab 3 
mg/kg. No patient experienced DLT. Larger 
studies with ipilimumab 10 mg/kg and SRS 
are warranted.
INTRODUCTION
Brain metastases (BM) occur in more 
than half of patients with advanced 
melanoma, and central nervous system 
disease burden often contributes to their 
death.1,2 The historic median survival 
of patients with BM from melanoma is 
4.7 months.3 Traditional BM treatment 
options includes surgery, whole brain 
radiation therapy (WBRT), and stereo-
tactic radiosurgery (SRS), and can prevent 
neurological decline and may also 
improve overall (OS).4-7 There has been 
increasing interest in radiotherapy (RT) 
combined with immunotherapy (IT) with 
growing evidence supporting a potential 
synergistic effect. It remains unclear the 
role that this synergism has on toxicity.8
Activated T-cells and antibodies targeting 
tumor-associated antigens (TAAs) 
detected in blood from cancer patients 
supports an active role for an anti-tumor 
immune response.9 T-cell infiltrates in 
melanoma have prognostic significance, 
and when identified within nodal metas-
tases, predict benefit in patients treated 
with neoadjuvant interferon-α-2b.10-13 
Cytotoxic T-lymphocyte-associated antigen 
4 (CTLA-4), is a negative regulator of 
T-cell-mediated anti-tumor immune 
responses and therefore represents a 
critical checkpoint, controlling both 
response duration and intensity.14-16 Ipili-
mumab (MDX-010, Bristol-Myers Squibb) 
is a fully human monoclonal antibody 
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Dose-Escalation Scheme
Ipilimumab was administered intrave-
nously over 90 minutes once every 3 
weeks for 4 total doses and was dose-
escalated independently in each arm 
with no intra-patient escalation. The FDA 
approved dose of 3 mg/kg was the starting 
dose. Rationale for ipilimumab dose esca-
lation to 10mg/kg was based on findings 
from the randomized, double-blind, 
phase 2 dose-ranging study of ipilim-
umab monotherapy demonstrating the 
best overall response rate in the 10 mg/
kg group (11.1%, 95% CI 4.9-10.7) versus 
the 3 mg/kg group (4.2%, 95% CI 0.9-11.7), 
suggesting further investigation of this 
higher dose.26 Following the initial 4 treat-
ments, maintenance dosing was offered 
to patients without unacceptable toxicity 
(refractory grade > 3 immune-related 
adverse events [irAEs]) at the same dose 
level given every 12 weeks until disease 
progression, toxicity requiring discontinu-
ation, or consent withdrawal.
Dose-Limiting Toxicity
Adverse events (AEs) were recorded with 
the Common Terminology Criteria for 
Adverse Events version 4.0 (CTCAE v.4). 
Dose-limiting toxicity (DLT) was defined 
as any grade 3 or higher treatment related 
toxicity occurring within 30 days of 
completing RT. Any neurological toxicity 
of grade 3, 4, or 5 was considered dose-
limiting (except symptoms present prior to 
study enrollment or expected sequelae of 
surgery or SRS). All patients were followed 
for AEs for 4 weeks following the last dose 
of ipilimumab. Intratumoral hemorrhage 
clinical trial was performed between 
October 2012 and August 2014, at 
Thomas Jefferson University and Ohio 
State University. All patients were over 18 
years old, Eastern Cooperative Oncology 
Group (ECOG) performance status 0 or 1, 
with normal hepatic and renal function 
and with histologic and radiographic 
confirmation of diagnosis. Blood count 
requirements were as follows: absolute 
neutrophil count ≥ 1000/µL, hemoglobin 
≥ 9g/dL, platelets ≥ 75,000/µL. Patients 
were excluded if they had a history of 
chronic infection (HIV or Hepatitis), 
autoimmune condition, abnormal 
thyroid function, or leptomeningeal 
carcinomatosis.
Radiotherapy
Patients were enrolled onto one of two 
arms depending on their IC disease 
burden. Arm A (WBRT) included patients 
with 5 or more BM, any lesion >4 cm 
maximal diameter, or 1 completely 
resected BM with postoperative cavity >4 
cm. Arm B (SRS) included patients with 
fewer than 5 BM (all ≤4 cm in diameter) 
or a single postoperative cavity <4 cm. 
Within each arm, RT dose was prede-
termined. WBRT dose was 30 Gy in 10 
fractions. Ipilimumab was administered 
on day 3 of RT in Arm A. Arm B patients 
received SRS according to the maximum 
diameter of the BM or resection cavity 
according to dose prescriptions in RTOG 
90-05.25 Ipilimumab was administered 
2 days following SRS in Arm B (Figure 1).
directed against the CTLA-4 receptor and 
is FDA approved for patients with unre-
sectable or metastatic melanoma.17,18,19 
One of the larger studies to investigate 
ipilimumab evaluated 127 patients and 
demonstrated an OS benefit (93 v. 42 
weeks, P=0.0028) for patients who 
received concomitant IT and RT.20 
Early in vitro studies showing a broad 
shoulder in the cell survival curves and a 
high repair rate in melanoma cells have 
inferred better tumor response with 
higher radiation doses.21,22 Moreover, SRS 
delivery in close proximity to IT yields the 
possibility of increased immunomodula-
tion which has been hypothesized to 
have an effect on distant control. This 
so-called “abscopal effect” is rare and 
intriguing, although specific mechanisms 
are currently incompletely under-
stood.23,24 In addition to the potential 
immunogenic advantages, concomitant 
treatment also limits delays in subsequent 
therapy.
To the best of our knowledge, we report 
the first prospective phase I study evalu-
ating concurrent ipilimumab with SRS or 
WBRT for patients with melanoma BM, 
assessing the safety and tolerability of 
concomitant therapy as well as intra-
cranial (IC) and extracranial (EC) control, 
progression-free survival (PFS), and OS.
MATERIALS AND METHODS
Study Design and Participants
This IRB-approved, open-label, phase I, 
Figure 1.  Treatment Schedule
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death or last patient contact (censored 
observation). Analysis of EC control, 
new BM development, and safety/toler-
ability was done separately for each arm. 
All subjects enrolled in the study who 
received at least one dose of ipilimumab 
were analyzed.
Role of the Funding Source
This study was funded by Bristol-Myers 
Squibb (New York City, NY) which 
provided the study drug and worked 
with the senior authors in the design 
and analysis. All authors jointly approved 
this work for submission and confirm 
the accuracy of the data. No additional 
authors not listed contributed to this 
work. All authors affirm that this trial 
was performed in accordance with the 
protocol and all amendments.
RESULTS
Patient Characteristics
Of the 26 patients screened for the trial, 
17 signed informed consent and were 
deemed eligible. One patient never 
received protocol therapy due to deterio-
rating health following consent. Sixteen 
patients received study therapy and were 
analyzed (Figure 2). Table 1 summarizes 
the patient and clinical characteristics, 
separately for the two arms. Overall, the 
mean age at time of BM diagnosis was 60 
(SD, 5-13) and 75% of the patients were 
male. There were 8 patients each with 
ECOG performance status of 0 and 1. 
Nine patients (56%) had initial BM surgery. 
Thirteen patients (81%) had EC metas-
tases at the time of BM diagnosis and 5 
(38%) received RT for their EC disease.
In Arm A (WBRT, n=5), the median 
number of lesions was 6 (range, 1 to >10) 
and the dose was 30 Gy in 10 fractions 
for all patients. In Arm B (SRS, n=11, the 
median number of lesions was 2 (range, 
1 to 3) and the median dose was 24 Gy 
(range, 15 to 24 Gy). In total, 20 lesions/
cavities were treated with SRS with a 
median planning target volume of 3.25 
cc per individual lesion (range, 0.1-22.7 
cc). The median per patient treatment 
volume was 8.5 cc (range 0.5-29.2 
cc). The median number of completed 
cycles of ipilimumab was as follows: 4 
(range, 2 - 4+14 maintenance) for dose 
level 3 mg/kg (n=7), and 3 (range, 2 - 4 
accrual of up to 12 patients for each arm, 
with up to 9 patients accrued from either 
Thomas Jefferson University or Ohio 
State University. Initially 3 patients were 
enrolled at the 3 mg/kg level. If none of 
these patients experienced a DLT, enroll-
ment continued to the 10 mg/kg level. 
If 1 of the 3 experienced toxicity at that 
level, 3 additional patients were accrued 
to the initial dose level. While waiting to 
complete the toxicity assessment for 
each triplet, additional patients could 
be accrued on the same dose, although 
their outcome was not considered for 
dose escalation purposes. No patient was 
treated at a higher dose until the 3 or 6 
patients completed their toxicity evalua-
tion period at the current dose. 
Data were analyzed separately for the 
two arms. Kaplan-Meier estimates for 
OS and PFS were computed in Stata 14 
(StataCorp, College Station, TX). PFS was 
analyzed from the date of SRS (or first day 
of WBRT) to the date of recurrence or 
progression. OS was analyzed from the 
date of first RT fraction to the date of 
was defined as new or worsening signs 
of bleeding within the irradiated tumor or 
cavity volume.
Assessment of Efficacy 
Contrast-enhanced MRI of the brain was 
performed at week 7 and then every 2 
months for 1 year, then every 3 months. 
All MRIs were interpreted using Response 
Evaluation Criteria In Solid Tumors 
(RECIST, version 1.1)27 and immune-
related response criteria (irRC).28 Overall 
response using irRC was classified as 
immune-related complete response 
(irCR), partial response (irPR), stable 
disease (irSD), or progressive disease 
(irPD) based on the predefined combi-
nation of parameters.28 For evaluation of 
EC disease, CT of the chest, abdomen, 
and pelvis was performed at week 7 and 
13 following enrollment, and every 3 
months subsequently.
Statistical Methodology
A two-stage 3+3 accrual design29 was 
used at each dose considered with goal 
Figure 2.  Consort Diagram
26 patients screened
9 screen failures
16 assigned 
treatment & analyzed
lpilimumab 
3 mg/kg
4 in analysis 
3 died; 1 alive
lpilimumab 
10 mg/kg
1 in analysis 
1 alive
lpilimumab 
10 mg/kg
8 in analysis 
21 died; 6 alive
17 deemed eligible 
and consented
1 patient never 
recieved study terapy 
due to deteriorating health
Arm A, WRBT 
n=5
Arm A, WRBT 
n=5
lpilimumab 
3 mg/kg
3 in analysis 
1 died; 2 alive
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maintenance) for dose level 10 mg/kg 
(n=9). Two patients in both arms received 
pre-treatment dexamethasone (mean 
dose 6 mg/day and 3.5 mg/day in the SRS 
and WBRT arms, respectively).
Toxicity
Ipilimumab in combination with RT 
was well tolerated. There were 21 
grade 1-2 neurotoxic effects including 
the following: headache (n=6, 37.5%), 
nausea/vomiting (n=3, 18.8%), subclinical 
intracranial hemorrhage (n=4, 25%), 
dizziness (n=1, 6.3%), vision changes 
(n=1, 6.3%), tinnitus/hearing loss (n=3, 
18.8%), facial palsy (n=1, 6.3%), weak-
ness/neuropathy (n=1, 6.3%), and seizure 
(n=1, 6.3%). There were no documented 
reports of pseudoprogression in our 
small sample of patients.
One patient experienced headache 
prompting emergency room evaluation, 
categorized as a grade 3 neurotoxic 
event. This toxicity occurred following 
SRS but prior to first IT administration 
and was therefore not considered a 
dose-limiting toxicity (DLT), but rather, 
an effect of surgery and SRS. The patient 
went on to receive 4 doses of ipilim-
umab plus one maintenance cycle prior 
to disease progression. There were no 
additional grade 3 neurotoxicities.
Table 2 summarizes the AEs in detail. 
In addition to the neurotoxicity above, 
there were 10 additional grade 3 toxici-
ties, including gastrointestinal most 
commonly (n=5, 31%). There were 
no grade 4 or 5 toxicities. Of note, no 
patients experienced radionecrosis.
Progression-Free Survival and 
Overall Survival
Median follow-up time was 8.0 months 
in Arm A (range, 3.5 to 24.1) and 10.5 
months in Arm B (range, 1.8 to 36.8) from 
first day of RT to last follow-up or death. 
At time of analysis, no patients were 
still on treatment. Fourteen patients in 
total progressed and/or died during the 
study’s follow-up (5/5 = 100% in Arm 
A and 9/11 = 82% in Arm B). Thirteen 
patients had IC progression (including 
the 6 who subsequently died). Median 
time to IC progression was 2.53 months 
(WBRT, range 0.3-18) versus 2.45 months 
(SRS, range 1-37). Overall response 
intracranially as defined by the irRC (15 
Figure 3.  Progression-free survival for the SRS and WBRT patients
	
	
Table 1.  Baseline Patient, Lesion, and Treatment Characteristics
Characteristic Value
Patients (n=16)
Mean age at IC diagnosis (range) 60 (37-75)
Sex, No. (%) Male 13 (81%)
Female 3 (19%)
ECOG performance status (n) 0 8
1 7
2 1
Number with extracranial metastases 13 (81%)
Number with pre-RT surgery 8 (50%)
Radiation technique WBRT 5 (31%)
Median # lesions (range) 6 (1->10)
SRS 11 (19%)
Median # lesions (range) 2 (1-3)
Median dose, Gy (range) 24 (15-24)
Ipilimumab Dose 3 mg/kg 9
Median # cycles completed (range) 4 (2-4+14 mainte-
nance)
Dose 10 mg/kg 7
Median # cycles completed (range) 3 (2-4)
Median length of follow-up after RT, months (range) 9.1 (2-37)
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with treatment sites as follows: lung (n=2), 
thoracic/lumbar vertebrae and lower 
leg soft tissue metastasis (n=1). Of the 3 
patients with no EC disease at the time of 
BM diagnosis, all 3 remained without EC 
disease at 2 month follow-up. Overall, 6 
patients experienced EC progression at 
2 months, 5 patients had stable disease, 
3 patients continued with no EC disease, 
1 patient had a partial response (after 
having her EC disease treated), and 1 
patient did not receive systemic imaging 
at the 2 month time point.
Seven patients developed new BM (as 
differentiated from previously treated BM) 
on follow-up imaging (Arm A, n=1 and Arm 
B, n=6) with the median time from first RT 
fraction to new BM diagnosis of 1.9 months 
(range, 0.97 to 8.2). The median time from 
first RT fraction to development of new BM 
in the one patient having received WBRT 
was 8.2 months.
DISCUSSION
To the best of our knowledge, we report 
the first prospective phase I study evalu-
ating concurrent ipilimumab with SRS or 
WBRT for patients with melanoma BM. 
The toxicity profile of escalating doses 
of ipilimumab demonstrated no grade 
4/5 toxicity, radionecrosis, or DLTs. Ipili-
mumab 10 mg/kg with SRS is safe and we 
recommend this dose for further study 
with concurrent SRS. Additional phase I 
studies will be necessary to determine 
the safety of WBRT with ipilimumab 10 
mg/kg, as we had to terminate this part 
of the trial due to slow accrual, however 
safety was demonstrated with concur-
rent WBRT and ipilimumab 3 mg/kg.
CA184-04230 was a phase II trial that 
evaluated ipilimumab in patients with 
melanoma BM. Patients were specifically 
excluded from the trial if they received 
any RT within 14 days of ipilimumab 
and only 8% of patients had received 
prior SRS.  There were no unexpected 
toxicities and activity was demonstrated 
particularly when BM were small and 
asymptomatic.30 However, this trial does 
not specifically evaluate the safety of 
concurrent RT and ipilimumab.
Hodi et al18 reported a large study evalu-
ating 676 patients randomized to receive 
ipilimumab 3 mg/kg in combination 
with an investigational peptide vaccine 
= 60% in Arm A and 3/11 = 27% in Arm 
B). Cause of death for these patients was 
as follows: urosepsis (n=1), cardiac arrest 
(n=1), hemorrhagic progression of BM 
(n=2), IC progression (n=1), EC progres-
sion (small bowel rupture secondary to 
tumor, n=1).
Median OS was 8 months in Arm A and 
not reached in Arm B (Figure 4).
Of the 13 patients with EC metastases 
at the time of BM diagnosis, 3 patients 
received targeted RT to the EC disease 
evaluable patients) was a follows: irSD 
(n= 5, 33%), irPD (n=9, 60%), irPR (n=1, 
7%). Following SRS, of the patients who 
experienced new BM or progression of 
existing BM (n=8), salvage treatment was 
as follows: 4 received salvage WBRT, 3 
received further SRS, and one patient 
received no further IC treatment. All 
patients who failed following WBRT 
received SRS as salvage.
Median PFS time was 2.5 months in Arm 
A and 2.1 months in Arm B (Figure 3). 
Six patients died during follow-up (3/5 
Table 2.  Adverse effects in SRS (n=11) and WBRT (n=5) arms
Grade 1 – 2 Grade 3 Grade 4
SRS WBRT SRS WBRT SRS WBRT
Headache 4 2 1 0 0 0
Post-treatment subclinical intracranial 
hemorrhage
4 0 0 0 0 0
Nausea, vomiting, abdominal pain 2 1 0 0 0 0
Fatigue 1 1 0 1 0 0
Hearing loss, otitis, tinnitus 1 2 0 0 0 0
Skin reaction, pruritis 2 3 0 0 0 0
Diarrhea 3 2 4 1 0 0
Insomnia 0 1 0 0 0 0
Anorexia 1 2 0 0 0 0
Hot flashes 0 1 0 0 0 0
Constipation 0 1 0 0 0 0
Lymphopenia 1 0 0 1 0 0
Visual changes 0 1 0 0 0 0
Hypophysitis 0 0 0 1 0 0
Hypertension 0 1 0 0 0 0
Alopecia 0 2 0 0 0 0
Dizziness 0 1 0 0 0 0
Bone pain 0 1 0 0 0 0
Anemia 1 1 1 0 0 0
Thrombocyopenia 1 0 0 0 0 0
Depression 1 0 0 0 0 0
Lipase increase 1 0 0 0 0 0
Weakness, neuropathy 1 0 0 0 0 0
Seizure 1 0 0 0 0 0
Facial palsy 1 0 0 0 0 0
Pleuritic pain, effusion 1 0 0 0 0 0
Abbreviations: SRS=stereotactic radiosurgery; WBRT=whole brain radiation therapy.
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Seven of the 13 patients treated concur-
rently had documented hemorrhage 
partially accounting for the enlarge-
ment and 2 lesions had documented 
recurrence. Of note, the IT was not 
standardized in this retrospective review 
and included ipilimumab, nivolumab, 
and pembrolizumab.32
Kiess et al.33 retrospectively reported 
response and toxicity on 46 patients with 
melanoma BM who received ipilimumab 
(3 mg/kg or 10 mg/kg) with SRS (median 
dose 21 Gy) between 2005 and 2011. 
Patients treated with SRS either before 
or during ipilimumab had improved OS 
compared to those having SRS afterward 
(1-year OS 56% vs 65% vs 40%, p=0.008). 
Moreover, only approximately 20% of 
patients experienced grade 3 or 4 toxicities. 
Interestingly, SRS before or during IT was 
more likely to be associated with a tempo-
rary increase in size or hemorrhage of the 
irradiated lesion, likely secondary to inflam-
mation, and asymptomatic in the majority 
of cases.33 Most likely due to the small 
numbers in our study and the frequency 
of neurosurgical intervention prior to SRS 
(6/11 patients, 55%), we did not observe the 
same temporary lesional edema following 
combination therapy. Similarly, no lesions 
were deemed to undergo pseudoprogres-
sion following SRS.
When evaluating the effects of IT, EC 
disease control is also of interest. First 
described in the 1950s, the abscopal 
effect refers to the seldom-reported 
phenomenon of tumor regression of a 
secondary site following RT to a sepa-
rate primary site.34 Seromic analysis and 
immunologic correlates of the abscopal 
effect in a patient with melanoma has 
demonstrated antigenic targets with 
increased antibody responses following 
RT.35 The surprising response achieved 
by the patient in this report provided new 
insight in the mechanisms of combina-
tion therapy. Our study evaluated EC 
control as a secondary endpoint with 
a similar hypothesis that IT delivered in 
close proximity to SRS may impact distant 
control. In our study, we did not observe 
the abscopal effect extracranially or intra-
cranially at non-target sites. 
Limitations of our study include slow 
accrual to Arm A, leading to its early closure. 
This arm did show safety with ipilimumab 3 
mg/kg, however. An additional caveat to 
and a 1-year OS of 65% versus 30% 
(p<0.0001).31
In terms post-RT lesion size, reports with 
combined therapy have been conflicting. 
Qian et al.8 recently reported results 
regarding 313 melanoma BMs in 53 
patients treated concurrently (defined 
as RT and IT delivery within 4 weeks 
of each other).8 IT was as follows: 54 
patients (72%) received anti-CTLA-4 
and 21 patients (28%) received anti-
PD-1. No patients received combination 
IT. The median percent reduction in 
lesion volume was significantly greater 
for the concurrent group. The timing 
of IT and SRS did not appear to effect 
post-treatment lesion size.8 In this 
report, only 39 lesions in 24 patients 
demonstrated regrowth to >120% base-
line volume. Authors concluded that the 
early response is greater and more rapid 
with concurrent therapy. There was not 
specific mention of tumor hemorrhage 
in this study.8 In contrast to this report, 
preliminary data reported by Shen et al. 
showed an increase in lesion size in 13 of 
26 lesions treated concurrently (defined 
as IT starting “prior to or with SRS”).32 
Lesion enlargement in the SRS alone 
cohort occurred with similar frequency. 
(gp100), ipilimumab alone, or gp100 
alone. OS was 10.0 months in patients 
receiving ipilimumab plus gp100, 
compared to 10.1 months in the ipilim-
umab alone arm and 6.4 months in the 
gp100 alone arm (p<0.001). Eighty-two 
patients (12.1%) had CNS disease in this 
study.18  This data is comparable to our 
study with the median OS not reached 
in the SRS arm and 8 months in the 
WBRT arm (median follow-up 10.5 and 
8 months, respectively). Given that OS 
has not been reached in the SRS arm 
of our trial, we hypothesize that the 
timing of ipilimumab in close proximity 
to SRS may mechanistically promote 
duration and intensity of response in 
these patients, although this study is 
hypothesis-generating in that regard.
To this end, a recent report by Johnson 
et al.31 demonstrated the impact of 
systemic agents on the clinical outcomes 
of patients with BM. Although this review 
included patients with many primary 
tumor types, and a variety of agents 
(BRAF inhibitors, ipilimumab in patients 
with melanoma primaries), the authors 
did show that patients receiving IT 
with SRS compared to SRS alone had a 
median survival of 18 versus 7 months 
Figure 4.  Overall survival for the SRS and WBRT patients
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development was 10.2 months (range, 
2.8-22.1 months), which is slightly shorter 
than the median follow-up in our SRS 
arm.40 Therefore, although our study 
does have relatively short follow-up, it is 
worthwhile to demonstrate that we have 
no documented cases of radionecrosis.
In an era where combined modality 
targeted therapy is becoming more 
promising and increasingly utilized, it is 
important to establish the safety profiles 
of these modalities.41 Our results demon-
strate the safety of combining SRS with 
either ipilimumab 3 mg/kg or 10 mg/kg. 
Future exploration of multi-agent immu-
notherapy in combination with SRS for 
melanoma BM is warranted, although 
currently there are no clinical trials open 
to accrual evaluating the safety and effi-
cacy of this combination of treatment.
therapy or pembrolizumab alone.
An additional limitation is the relatively 
short follow-up possibly limiting the 
capture of late toxicity. The median 
follow-up in the arm receiving SRS was 
10.5 months which may be long enough 
to catch some, but not all cases of radio-
necrosis. A recent report by Colaco et 
al.40 evaluating 180 patients with BM who 
received radiosurgery with either cyto-
toxic chemotherapy, targeted therapy, 
or IT noted a significantly increased rate 
of radionecrosis or treatment-related 
imaging changes in the IT group (OR 
2.40 [95% CI 1.06–5.44]; p = 0.03).40 The 
median follow-up was 11.7 months and 
31% of patients had melanoma primaries. 
Of importance, 30% of patients received 
prior WBRT which increases one’s risk 
for subsequent radionecrosis following 
radiosurgery. For patients who received 
IT alone, median time to radionecrosis 
our study is that ipilimumab alone is no 
longer the standard of care for previously 
untreated advanced melanoma. First-line 
therapy is now either anti-programmed 
death 1 (PD-1) inhibitor monotherapy 
(pembrolizumab or nivolumab) or a 
combination of nivolumab with ipilim-
umab.36 This combination of therapies 
improved overall response rate and 
PFS as compared with either treatment 
alone, however, demonstrated signifi-
cantly increased toxicity. Compared 
to single agent therapy, the effect of 
combination therapy on OS has not yet 
been demonstrated.37,38 Pembrolizumab 
alone demonstrated prolonged PFS and 
OS and had less high-grade toxicity as 
compared to ipilimumab in patients with 
advanced melanoma as demonstrated in 
the KEYNOTE-006 trial.39 Based on these 
results, future studies will need to address 
RT with combination checkpoint inhibitor 
Table 3.  Previously reported series of melanoma brain metastases treated with immunotherapy.
Primary 
author
Year Analysis type Primary Patients 
who got 
SRS (n)
IT agent/timing Patients 
receiving IT 
and SRS (%)
Median 
survival 
(months)
OS Other
Knisely41 2012 Prospectively 
collected, 
retrospectively 
melanoma 7 Ipilimumab (SRS first, 
n=16; IT first, n=11)
27 (35%) 21.3 (with IT) 
v. 4.9 (no IT)
2 year: 47.2% 
(with IT) v. 
19.7% (no IT) 
p=0.044
Grade ≥3 
toxicity NR
Johnson3 2015 retrospective renal cell, 
melanoma, 
breast, colon, 
esophagus, 
lung
737 various agents 
(including BRAF 
inhibitors & 
ipilimumab), IT 
concurrently or within 
30 days of SRS
167 (23%) 18 (with IT) 
v. 7 (no IT)
1 year: 65% 
(with IT) v. 
30% (no IT) 
p<0.0001
Grade ≥3 
toxicity NR
Kiess3 2015 retrospective melanoma 46 Ipilimumab (concur-
rent, n=15; SRS first, 
n=19; IT first, n=12)
46 (100%) 12.4 
(all patients)
1 year: 65% 
(concurrent) 
v. 56% (SRS 
before)  v. 40% 
(IT before)
P=0.008
1 year 
RR: 69% 
(concurrent) 
v. 64% (SRS 
before)  v. 
92% (IT 
before)
P=0.003
Patel42 2015 retrospective melanoma 54 Ipilimumab (within 4 
months of SRS)
20 (37%) 9.1 (with IT) v. 
8.0 (no IT) 
p=0.84
NA 1 year LC: 
71.4% (with 
IT) v. 92.3% 
(no IT)
p=0.40
NR: not reported; IT: immunotherapy; RR: regional recurrence
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